Literature DB >> 32974687

MR 4D flow-based mean pulmonary arterial pressure tracking in pulmonary hypertension.

Ursula Reiter1, Gabor Kovacs2,3, Clemens Reiter4, Corina Kräuter4,5, Volha Nizhnikava4, Michael Fuchsjäger4, Horst Olschewski2,3, Gert Reiter4,6.   

Abstract

OBJECTIVES: Longitudinal hemodynamic follow-up is important in the management of pulmonary hypertension (PH). This study aimed to evaluate the potential of MR 4-dimensional (4D) flow imaging to predict changes in the mean pulmonary arterial pressure (mPAP) during serial investigations.
METHODS: Forty-four adult patients with PH or at risk of developing PH repeatedly underwent routine right heart catheterization (RHC) and near-term MR 4D flow imaging of the main pulmonary artery. The duration of vortical blood flow along the main pulmonary artery was evaluated from MR 4D velocity fields using prototype software and converted to an MR 4D flow imaging-based mPAP estimate (mPAPMR) by a previously established model. The relationship of differences between RHC-derived baseline and follow-up mPAP values (ΔmPAP) to corresponding differences in mPAPMR (ΔmPAPMR) was analyzed by means of regression and Bland-Altman analysis; the diagnostic performance of ΔmPAPMR in predicting mPAP increases or decreases was investigated by ROC analysis.
RESULTS: Areas under the curve for the prediction of mPAP increases and decreases were 0.92 and 0.93, respectively. With the natural cutoff ΔmPAPMR = 0 mmHg, mPAP increases (decreases) were predicted with an accuracy, sensitivity, and specificity of 91% (91%), 85% (89%), and 94% (92%), respectively. For patients in whom 4D flow allowed a point estimate of mPAP (mPAP > 16 mmHg), ΔmPAPMR correlated strongly with ΔmPAP (r = 0.91) and estimated ΔmPAP bias-free with a standard deviation of 5.1 mmHg.
CONCLUSIONS: MR 4D flow imaging allows accurate non-invasive prediction and quantification of mPAP changes in adult patients with PH or at risk of developing PH. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00575692 and NCT01725763 KEY POINTS: • MR 4D flow imaging allows accurate non-invasive prediction of mean pulmonary arterial pressure increases and decreases in adult patients with or at risk of developing pulmonary hypertension. • In adult patients with mean pulmonary arterial pressure > 16 mmHg, MR 4D flow imaging allows estimation of longitudinal mean pulmonary arterial pressure changes without bias with a standard deviation of 5.1 mmHg.

Entities:  

Keywords:  Follow-up studies; Hemodynamics; Magnetic resonance imaging; Pulmonary hypertension

Mesh:

Year:  2020        PMID: 32974687      PMCID: PMC7979582          DOI: 10.1007/s00330-020-07287-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  35 in total

Review 1.  Treatment goals of pulmonary hypertension.

Authors:  Vallerie V McLaughlin; Sean Patrick Gaine; Luke S Howard; Hanno H Leuchte; Michael A Mathier; Sanjay Mehta; Massimillano Palazzini; Myung H Park; Victor F Tapson; Olivier Sitbon
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

2.  Correlation of native T1 mapping with right ventricular function and pulmonary haemodynamics in patients with chronic thromboembolic pulmonary hypertension before and after balloon pulmonary angioplasty.

Authors:  F C Roller; S Kriechbaum; A Breithecker; C Liebetrau; M Haas; C Schneider; A Rolf; S Guth; E Mayer; C Hamm; G A Krombach; C B Wiedenroth
Journal:  Eur Radiol       Date:  2018-08-29       Impact factor: 5.315

3.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

4.  Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry.

Authors:  Andrew J Swift; Smitha Rajaram; Robin Condliffe; Dave Capener; Judith Hurdman; Charlie A Elliot; Jim M Wild; David G Kiely
Journal:  J Cardiovasc Magn Reson       Date:  2012-06-21       Impact factor: 5.364

5.  Non-invasive methods for estimating mPAP in COPD using cardiovascular magnetic resonance imaging.

Authors:  C S Johns; S Rajaram; D A Capener; C Oram; C Elliot; R Condliffe; D G Kiely; J M Wild; A J Swift
Journal:  Eur Radiol       Date:  2017-11-16       Impact factor: 5.315

6.  Accuracy of echocardiographic indices for serial monitoring of right ventricular systolic function in patients with precapillary pulmonary hypertension.

Authors:  Takahiro Sato; Ichizo Tsujino; Hiroshi Ohira; Noriko Oyama-Manabe; Yoichi M Ito; Chisa Takashina; Taku Watanabe; Masaharu Nishimura
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

7.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 8.  Quantitative magnetic resonance imaging of pulmonary hypertension: a practical approach to the current state of the art.

Authors:  Andrew J Swift; Jim M Wild; Scott K Nagle; Alejandro Roldán-Alzate; Christopher J François; Sean Fain; Kevin Johnson; Dave Capener; Edwin J R van Beek; David G Kiely; Kang Wang; Mark L Schiebler
Journal:  J Thorac Imaging       Date:  2014-03       Impact factor: 3.000

9.  Native myocardial T1 mapping in pulmonary hypertension: correlations with cardiac function and hemodynamics.

Authors:  Ursula Reiter; Gert Reiter; Gabor Kovacs; Gabriel Adelsmayr; Andreas Greiser; Horst Olschewski; Michael Fuchsjäger
Journal:  Eur Radiol       Date:  2016-04-27       Impact factor: 5.315

10.  Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry.

Authors:  Andrew J Swift; Smitha Rajaram; Judith Hurdman; Catherine Hill; Christine Davies; Tom W Sproson; Allison C Morton; Dave Capener; Charlie Elliot; Robin Condliffe; Jim M Wild; David G Kiely
Journal:  JACC Cardiovasc Imaging       Date:  2013-06-13
View more
  3 in total

Review 1.  ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly.

Authors:  Mona Lichtblau; Lucilla Piccari; Sheila Ramjug; Aleksandar Bokan; Benoit Lechartier; Etienne-Marie Jutant; Margarida Barata; Agustin Roberto Garcia; Luke S Howard; Yochai Adir; Marion Delcroix; Luis Jara-Palomares; Laurent Bertoletti; Olivier Sitbon; Silvia Ulrich; Anton Vonk Noordegraaf
Journal:  ERJ Open Res       Date:  2022-05-23

2.  Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension.

Authors:  Gert Reiter; Gabor Kovacs; Clemens Reiter; Albrecht Schmidt; Michael Fuchsjäger; Horst Olschewski; Ursula Reiter
Journal:  Front Cardiovasc Med       Date:  2022-08-03

3.  Correlation between Pulmonary Artery Pressure and Vortex Duration Determined by 4D Flow MRI in Main Pulmonary Artery in Patients with Suspicion of Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Authors:  Jean-François Deux; Lindsey A Crowe; Léon Genecand; Anne-Lise Hachulla; Carl G Glessgen; Stéphane Noble; Maurice Beghetti; Jin Ning; Daniel Giese; Frédéric Lador; Jean-Paul Vallée
Journal:  J Clin Med       Date:  2022-09-05       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.